 |
18 Diseases |  |
32 Trials |
|
32 Trials |  |
839 News |  |
| «12...45678910111213141516» |
- ||||| Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
New P4 trial: Revaccination With PNEUMOVAX (clinicaltrials.gov) - Oct 10, 2014
P4, N=240, Not yet recruiting, Sponsor: Merck Sharp & Dohme Corp.
- |||||| Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Enrollment open: Evaluation of the Safety and Immunogenicity of Sequential Administration of Prevnar 13 (clinicaltrials.gov) - Sep 16, 2014
P3, N=400, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Not yet recruiting --> Recruiting
- Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Enrollment closed, Trial primary completion date, IO biomarker, Surgery: Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Sep 15, 2014
P=N/A, N=26, Active, not recruiting, Sponsor: Mayo Clinic
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2014 --> Dec 2014
- Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Clinical: Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients (clinicaltrials.gov) - Sep 5, 2014
P=N/A, N=90, Active, not recruiting, Sponsor: University of California, Davis
- |||||||||| Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
New P3 trial: Evaluation of the Safety and Immunogenicity of Sequential Administration of Prevnar 13 (clinicaltrials.gov) - Aug 26, 2014
P3, N=400, Not yet recruiting, Sponsor: Merck Sharp & Dohme Corp.
- |||||||||| Fluarix Quadrivalent (influenza vaccine) / GSK
New P3 trial: Evaluation of the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine Influsplit (clinicaltrials.gov) - Aug 19, 2014
P3, N=356, Not yet recruiting, Sponsor: GlaxoSmithKline
- Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Enrollment open, Pneumococcal vaccines: Impact and Cost of a Pharmacist Pneumococcal Vaccination Program With PNEUMOVAX (clinicaltrials.gov) - Jul 30, 2014
P4, N=200, Recruiting, Sponsor: Thomas Jefferson University
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2014 --> Dec 2014 Not yet recruiting --> Recruiting
- | Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), Boostrix (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine) / GSK
Trial completion, Pneumococcal vaccines: PneuMum: Pneumococcal Vaccination of Australian Indigenous Mothers (clinicaltrials.gov) - Jul 12, 2014
P3, N=227, Completed, Sponsor: Menzies School of Health Research
Not yet recruiting --> Recruiting Recruiting --> Completed
- Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Trial primary completion date: StatVax: The Effect of Short-term Atorvastatin Treatment on Immune Responses to Pneumovax 23 (clinicaltrials.gov) - Jun 4, 2014
P4, N=24, Recruiting, Sponsor: University of Florida
Recruiting --> Completed Trial primary completion date: May 2014 --> Aug 2014
- Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Enrollment open: StatVax: The Effect of Short-term Atorvastatin Treatment on Immune Responses to Pneumovax 23 (clinicaltrials.gov) - Jun 4, 2014
P4, N=24, Recruiting, Sponsor: University of Florida
Trial primary completion date: May 2014 --> Aug 2014 Not yet recruiting --> Recruiting
- Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
Enrollment open: Systems Biology of PNEUMOVAX (clinicaltrials.gov) - May 28, 2014
P=N/A, N=88, Recruiting, Sponsor: Emory University
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- lenalidomide / Generic mfg.
Trial primary completion date: Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov) - May 8, 2014
P2, N=35, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Trial primary completion date: Feb 2017 --> Oct 2017
- | lenalidomide / Generic mfg.
Trial initiation date: Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov) - May 8, 2014
P2, N=35, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Feb 2017 --> Oct 2017 Initiation date: Feb 2014 --> Oct 2014
- |||| Boostrix (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine) / GSK, Menveo (meningococcal-groups A, C, W-135 and Y oligosaccharide CRM197 conjugate vaccine) / GSK
Enrollment open: A Protocol to Collect Human Serum Samples From Healthy Adults for Use as Quality Controls Samples in GlaxoSmithKline (GSK) Biologicals' Assays (clinicaltrials.gov) - Apr 16, 2014
P4, N=350, Recruiting, Sponsor: GlaxoSmithKline
Initiation date: Feb 2014 --> Oct 2014 Not yet recruiting --> Recruiting
- Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Clinical: PNEUMOVACB: Identifocation the B Cell Subsets Responsible for Anti-pneumococcal Response (clinicaltrials.gov) - Apr 14, 2014
P=N/A, N=24, Not yet recruiting, Sponsor: Institut National de la Santé Et de la Recherche Médicale, France
- |||||| Shingrix (zoster vaccine recombinant adjuvanted) / GSK, Japan Vaccine
Enrollment open: Study to Evaluate Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A When Co-administered With Pneumovax 23 (clinicaltrials.gov) - Mar 26, 2014
P3, N=864, Recruiting, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
New P4 trial: StatVax: The Effect of Short-term Atorvastatin Treatment on Immune Responses to Pneumovax 23 (clinicaltrials.gov) - Mar 25, 2014
P4, N=24, Not yet recruiting, Sponsor: University of Florida
- |||||||||| dimethyl fumarate / Generic mfg.
New P3 trial: Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis. (clinicaltrials.gov) - Mar 25, 2014
P3, N=68, Not yet recruiting, Sponsor: Biogen Idec
- | Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
New P4 trial, Pneumococcal vaccines: Effectiveness of the Pneumococcal Polysaccharide Vaccine in Military Recruits (clinicaltrials.gov) - Mar 4, 2014
P4, N=152723, Completed, Sponsor: Naval Health Research Center
- |||||||||| Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
New P3 trial, Pneumococcal vaccines: Study Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (clinicaltrials.gov) - Mar 3, 2014
P3, N=750, Enrolling by invitation, Sponsor: SK Chemicals Co.,Ltd.
- ||||| Boostrix (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine) / GSK, Menveo (meningococcal-groups A, C, W-135 and Y oligosaccharide CRM197 conjugate vaccine) / GSK
New P4 trial: A Protocol to Collect Human Serum Samples From Healthy Adults for Use as Quality Controls Samples in GlaxoSmithKline (GSK) Biologicals' Assays (clinicaltrials.gov) - Feb 24, 2014
P4, N=350, Recruiting, Sponsor: GlaxoSmithKline
- Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Trial completion, Pneumococcal vaccines: Pneumococcal Adult-dose Ranging Immunization Study (clinicaltrials.gov) - Feb 24, 2014
P1/2, N=220, Completed, Sponsor: Group Health Cooperative
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||| Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Trial initiation date, Pneumococcal vaccines: Early Versus Delayed Pneumococcal Vaccination in HIV (clinicaltrials.gov) - Feb 10, 2014
P1/2, N=79, Completed, Sponsor: CIHR Canadian HIV Trials Network
Active, not recruiting --> Completed Initiation date: Apr 2003 --> Sep 2004
- |||| Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Trial completion, Pneumococcal vaccines: Early Versus Delayed Pneumococcal Vaccination in HIV (clinicaltrials.gov) - Feb 10, 2014
P1/2, N=79, Completed, Sponsor: CIHR Canadian HIV Trials Network
Initiation date: Apr 2003 --> Sep 2004 Recruiting --> Completed
- |||||||||| Shingrix (zoster vaccine recombinant adjuvanted) / GSK, Japan Vaccine
New P3 trial: Study to Evaluate Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A When Co-administered With Pneumovax 23 (clinicaltrials.gov) - Jan 23, 2014
P3, N=864, Recruiting, Sponsor: GlaxoSmithKline
- Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
Enrollment change: Systems Biology of PNEUMOVAX (clinicaltrials.gov) - Jan 20, 2014
P=N/A, N=88, Not yet recruiting, Sponsor: Emory University
Recruiting --> Completed N=66 --> 88
- Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
IO biomarker, Pneumococcal vaccines: Mechanisms of Impaired HIV-associated B Cell and Pneumococcal Vaccine Responses (clinicaltrials.gov) - Dec 12, 2013
P=N/A, N=120, Not yet recruiting, Sponsor: University of Colorado, Denver
- | Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Trial completion, IO biomarker: A Phase III Clinical Trial to Study the Safety and Immunogenicity of Pneumovax (clinicaltrials.gov) - Nov 12, 2013
P3, N=102, Completed, Sponsor: Merck
N=66 --> 88 Active, not recruiting --> Completed
- | Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
Enrollment open, Pneumococcal vaccines: Pneumococcal Vaccine in Untreated CLL Patients (clinicaltrials.gov) - Oct 16, 2013
P3, N=154, Recruiting, Sponsor: Karolinska University Hospital
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
New P4 trial, Pneumococcal vaccines: Impact and Cost of a Pharmacist Pneumococcal Vaccination Program With PNEUMOVAX (clinicaltrials.gov) - Sep 15, 2013
P4, N=200, Not yet recruiting, Sponsor: Thomas Jefferson University
- || methotrexate / Generic mfg.
New P3 trial: VACIMRA: VACcination In Methotrexate Treated Rheumatoid Arthritis Patients (clinicaltrials.gov) - Sep 9, 2013
P3, N=276, Not yet recruiting, Sponsor: University Hospital, Montpellier
- | Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
New P4 trial, Pneumococcal vaccines: PneuVAC: Pneumococcal Vaccination of Crohn Patients (clinicaltrials.gov) - Sep 8, 2013
P4, N=150, Recruiting, Sponsor: Statens Serum Institut
- | lenalidomide / Generic mfg.
New P2 trial: Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov) - Aug 14, 2013
P2, N=35, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
Enrollment closed, Pneumococcal vaccines: Pneumococcal Adult Kinetics Study - Understanding the B Cell Response to Pneumococcal Vaccines (clinicaltrials.gov) - Aug 11, 2013
P3, N=4, Active, not recruiting, Sponsor: University of Oxford
Not yet recruiting --> Recruiting Not yet recruiting --> Active, not recruiting
- || Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
New P3 trial, Pneumococcal vaccines: Pneumococcal Vaccine in Untreated CLL Patients (clinicaltrials.gov) - Jul 2, 2013
P3, N=154, Recruiting, Sponsor: Karolinska University Hospital
- |||| Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), Vaxneuvance (15-valent pneumococcal conjugate vaccine) / Merck (MSD)
Trial completion: The Safety, Tolerability, and Immunogenicity Profiles of a Single Dose of V114, PNEUMOVAX (clinicaltrials.gov) - Mar 4, 2013
P2, N=692, Completed, Sponsor: Merck Sharp & Dohme Corp.
Not yet recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Enrollment change, Pneumococcal vaccines: Immune Responses to Pneumococcal Vaccination Among HIV-infected Subjects (clinicaltrials.gov) - Feb 19, 2013
P=N/A, N=107, Completed, Sponsor: Department of Veterans Affairs
Active, not recruiting --> Completed N=135 --> 107
- Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Trial completion, Pneumococcal vaccines: Immune Responses to Pneumococcal Vaccination Among HIV-infected Subjects (clinicaltrials.gov) - Feb 13, 2013
P=N/A, N=107, Completed, Sponsor: Department of Veterans Affairs
N=135 --> 107 Active, not recruiting --> Completed
- Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Trial completion: Humoral Determinants of Immunity to Pneumococcal Infection (clinicaltrials.gov) - Feb 13, 2013
P4, N=114, Completed, Sponsor: Daniel M. Musher MD
Active, not recruiting --> Completed Recruiting --> Completed
- | PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
New P4 trial: SOT13: Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine Compared to the Pneumococcal Polysaccharide Vaccine in Adult Kidney and Liver Transplant Patients (clinicaltrials.gov) - Jan 30, 2013
P4, N=150, Recruiting, Sponsor: Helsinki University Central Hospital
- ||| Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
New P1 trial: Study to Evaluate Safety, Reactogenicity and Immunogenicity of the Pneumococcal Protein PhtD Vaccine in Healthy Adults (clinicaltrials.gov) - Jan 10, 2013
P1, N=150, Completed, Sponsor: GlaxoSmithKline
- || Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
New P3 trial, IO biomarker: A Phase III Clinical Trial to Study the Safety and Immunogenicity of Pneumovax (clinicaltrials.gov) - Nov 25, 2012
P3, N=102, Completed, Sponsor: Merck
- |||| Actemra IV (tocilizumab) / Roche, JW Pharma
Trial completion: A Study of the Effects of RoActemra/Actemra on Vaccination in Patients With Rheumatoid Arthritis on Background Methotrexate (VISARA) (clinicaltrials.gov) - Sep 27, 2012
P4, N=91, Completed, Sponsor: Genentech
Recruiting --> Completed Active, not recruiting --> Completed
- || PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
New P3 trial, Pneumococcal vaccines: Comparing the effectivity of two different pneumococcal vaccines against severe pneumococcal diseases in adult kidney and liver transplant patients (EUDRACT) - Aug 16, 2012
P3, N=150, Ongoing, Sponsor: HYKS-instituutti
- Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Trial completion: Prospective Trial of Vaccine Responses Against Pneumococcus and Influenza in Adult Cancer Patients 65 Years of Age and Older (clinicaltrials.gov) - Aug 7, 2012
P2, N=126, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Trial completion, Pneumococcal vaccines: PPV: Pneumococcal Polysaccharide Vaccine in Older Adults (clinicaltrials.gov) - Aug 1, 2012
P4, N=100, Completed, Sponsor: National Institute on Aging (NIA)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Enrollment change: PCVFU: Pneumococcal Conjugate Vaccine Followup (clinicaltrials.gov) - May 27, 2012
P2, N=280, Completed, Sponsor: William Pomat
Active, not recruiting --> Completed N=450 --> 280
- Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Trial completion: PCVFU: Pneumococcal Conjugate Vaccine Followup (clinicaltrials.gov) - May 27, 2012
P2, N=280, Completed, Sponsor: William Pomat
N=450 --> 280 Recruiting --> Completed
- ||||| Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Enrollment change, Pneumococcal vaccines: Revaccination With PNEUMOVAX(TM) 23 in Older Adults (V110-007) (clinicaltrials.gov) - Feb 16, 2012
P3, N=143, Completed, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Completed N=400 --> 143
- PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
New P3 trial, Pneumococcal vaccines: Trial of vaccine in HIV patients from 6 years old to older (EUDRACT) - Jan 30, 2012
P3, N=0, , Sponsor: Wyeth Pharmaceuticals Inc. (a Pfizer Company)